Testosterone Gel 1.62% + Testosterone Gel 1.62%

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypogonadism

Conditions

Hypogonadism

Trial Timeline

May 1, 2010 → Jul 1, 2010

About Testosterone Gel 1.62% + Testosterone Gel 1.62%

Testosterone Gel 1.62% + Testosterone Gel 1.62% is a phase 1 stage product being developed by AbbVie for Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT01133548. Target conditions include Hypogonadism.

What happened to similar drugs?

6 of 19 similar drugs in Hypogonadism were approved

Approved (6) Terminated (3) Active (12)
Topical Testosterone SolutionEli LillyApproved
AndroGel® + PlaceboAbbVieApproved
AndroGel 1.62%AbbVieApproved
NEBIDO + PLACEBOBayerApproved
JatenzoICON plc.Approved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01133548Phase 1Completed